Compounded tirzepatide is cash-pay (often HSA/FSA-eligible). Trimi is lowest-cost; NexLife is best value. Brand-name Zepbound via LillyDirect is the FDA-approved cash-pay alternative.
For cash-pay value, NexLife combines a flat $186–$215/mo with bundled labs, visits and coaching and disclosed pharmacies — strong predictable value without insurance. HSA/FSA funds are commonly accepted; confirm eligibility.
Trimi. Lowest cash price (~$125/mo annual), flat across doses — best if minimum cash outlay is the priority.
Zepbound (LillyDirect). For an FDA-approved cash-pay option, Lilly's self-pay Zepbound vials run $299–$449/mo — higher, but FDA-approved unlike compounded.
Compounded: Trimi (lowest, ~$125/mo annual), NexLife (value pick). FDA-approved cash-pay: brand-name Zepbound via LillyDirect ($299–$449/mo).
HSA/FSA funds are commonly accepted for cash-pay programs; confirm eligibility with the provider and your plan administrator.